These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 31765648)

  • 1. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review.
    Yaribeygi H; Sathyapalan T; Maleki M; Jamialahmadi T; Sahebkar A
    Life Sci; 2020 Jan; 240():117090. PubMed ID: 31765648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
    Gupta A; Mittal S; Monika ; Dhingra R; Dhingra N
    Curr Diabetes Rev; 2020; 16(7):716-732. PubMed ID: 31951170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review.
    Kalra S; Singh V; Nagrale D
    Adv Ther; 2016 Sep; 33(9):1502-18. PubMed ID: 27423646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter inhibitors and oxidative stress: An update.
    Yaribeygi H; Atkin SL; Butler AE; Sahebkar A
    J Cell Physiol; 2019 Apr; 234(4):3231-3237. PubMed ID: 30443936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors: molecular design and potential differences in effect.
    Isaji M
    Kidney Int Suppl; 2011 Mar; (120):S14-9. PubMed ID: 21358697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.
    D'Onofrio N; Sardu C; Trotta MC; Scisciola L; Turriziani F; Ferraraccio F; Panarese I; Petrella L; Fanelli M; Modugno P; Massetti M; Marfella LV; Sasso FC; Rizzo MR; Barbieri M; Furbatto F; Minicucci F; Mauro C; Federici M; Balestrieri ML; Paolisso G; Marfella R
    Mol Metab; 2021 Dec; 54():101337. PubMed ID: 34500107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibition--a novel strategy for diabetes treatment.
    Chao EC; Henry RR
    Nat Rev Drug Discov; 2010 Jul; 9(7):551-9. PubMed ID: 20508640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes.
    Yaribeygi H; Atkin SL; Sahebkar A
    Diabetes Metab Syndr; 2019; 13(2):1679-1683. PubMed ID: 31336541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i.
    Cianciolo G; De Pascalis A; Gasperoni L; Tondolo F; Zappulo F; Capelli I; Cappuccilli M; La Manna G
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32549243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naturally Occurring SGLT2 Inhibitors: A Review.
    Yaribeygi H; Ashrafizadeh M; Sathyapalan T; Jamialahmadi T; Sahebkar A
    Adv Exp Med Biol; 2021; 1328():523-530. PubMed ID: 34981503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.
    List JF; Whaley JM
    Kidney Int Suppl; 2011 Mar; (120):S20-7. PubMed ID: 21358698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
    Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
    Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class.
    Kaneto H; Obata A; Kimura T; Shimoda M; Kinoshita T; Matsuoka TA; Kaku K
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus.
    Geist BK; Brath H; Zisser L; Yu J; Fueger B; Nics L; Patronas EM; Kautzky-Willer A; Hacker M; Rasul S
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3034-3041. PubMed ID: 37195445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment.
    Rizzo MR; Di Meo I; Polito R; Auriemma MC; Gambardella A; di Mauro G; Capuano A; Paolisso G
    Pharmacol Res; 2022 Feb; 176():106062. PubMed ID: 35017046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The management of diabetes mellitus-imperative role of natural products against dipeptidyl peptidase-4, α-glucosidase and sodium-dependent glucose co-transporter 2 (SGLT2).
    Abbas G; Al Harrasi A; Hussain H; Hamaed A; Supuran CT
    Bioorg Chem; 2019 May; 86():305-315. PubMed ID: 30738330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.
    Palmiero G; Cesaro A; Vetrano E; Pafundi PC; Galiero R; Caturano A; Moscarella E; Gragnano F; Salvatore T; Rinaldi L; Calabrò P; Sasso FC
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.